Cardiff Oncology
Price
Prix
Questions fréquentes
Quelle est la capitalisation boursière de Cardiff Oncology ?
Quel est le bénéfice par action (BPA) de Cardiff Oncology ?
Quelles sont les évaluations des analystes et le prix cible de l'action Cardiff Oncology ?
Quel est le chiffre d'affaires de Cardiff Oncology sur les douze derniers mois ?
Quel est l'EBITDA de Cardiff Oncology ?
Quel est le flux de trésorerie disponible de Cardiff Oncology ?
Quel est le bêta à 5 ans de l'action Cardiff Oncology ?
Combien d'employés compte Cardiff Oncology, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Cardiff Oncology ?
Finances
Capitalisation boursière
127,83 M $USbêta sur 5 ans
1,91BPA (TTM)
-0,949 $USFree Float
47,76 MRecettes (TTM)
689,00 k $USEBITDA (TTM)
-46,00 M $USCash-flow disponible (TTM)
-34,65 M $USCotation
Notes des analystes
L'objectif de prix est de 10,50 $US et l'action est analysée par 4 analystes.
Acheter
4
Hold
0
Vendre
0
Informations
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
31
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire